Connexin37 (GJA4) genotype predicts survival after an acute coronary syndrome - 16/08/11
Résumé |
Background |
GJA4 1019 C > T, MMP3 −1171delA, and SERPINE1 −668delG genotypes have been associated with the risk of incident myocardial infarction. We tested the hypothesis that these genotypes would predict long-term mortality after an acute coronary syndrome (ACS).
Methods |
We assembled a prospective cohort study on 726 patients with ACS admitted between March 2000 and October 2001. Kaplan-Meier estimates and Cox proportional hazards models of 3-year mortality adjusted for age, race, ACS type, prior heart failure, diabetes, and revascularization were used to compare groups.
Results |
The GJA4 1019 C > T genotype was significantly related to mortality over 3 years (8.3% vs 14%, for the C/C vs T allele carriers; P = .02), with an adjusted hazard ratio of 1.7 (95% confidence interval 1.05-2.8, P = .03). This finding was consistent in both men and women (hazard ratio = 1.9 and 1.7, respectively) with no significant sex interaction (P = .8). The MMP3 −1171delA and SERPINE1 −668delG genotypes were not significantly related to mortality in the overall population (all P > .4).
Conclusions |
GJA4 1019 C > T genotype predicted risk of death after an ACS, whereas the MMP3 and SERPINE1 genotypes did not. The GJA4 1019 C > T polymorphism may warrant integration into comprehensive risk stratification algorithms for patients with ACS.
Le texte complet de cet article est disponible en PDF.Plan
This work was supported in part by R01 HS11282-01 from the Agency for Healthcare Research and Quality, the NIH Pharmacogenetics research network (U01 GM63340), a Heart Failure Society of America Research Fellowship grant, and NIH SCCOR (P50 HL077113). |
|
Dr Howard L. McLeod is a member of an advisory board for the US Food and Drug Administration. |
Vol 154 - N° 3
P. 561-566 - septembre 2007 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?